NCT04434560: Neoadjuvant Immunotherapy in Brain Metastases

Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: PD-L1
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have must have 1 to 3 previously untreated brain metastases that are less than or equal to 4 cm in the largest direction; Patient must be asymptomatic or minimally symptomatic – see trial for details

Comments are closed.

Up ↑